A genetic test developed at the University of California San Francisco (UCSF) can identify triple negative breast cancer patients who will and won’t respond to commonly used immunotherapies. Triple negative breast cancer accounts for up to 15% of all breast cancers and affects around 13 in 100,000 women in the…

A potential therapeutic target for triple negative breast cancer (TNBC) has been pinpointed by researchers at Virginian Commonwealth University (VCU) Massey Cancer Center. Importantly, this target may be effective in black patients, who suffer disproportionally from the disease. Further, the researchers may have a lead on a biomarker—c-MYC—to guide treatment.…

A natural compound, cardamonin, found in the spice cardamom and other plants, could have therapeutic potential for triple-negative breast cancer (TNBC), according to a new study using human cancer cells. The researchers also found that the compound targets a protein, PD-L1, that helps cancer cells elude the immune system. Further,…

Increasing scientific evidence supports the involvement of the enzyme MAPK4 in cancer growth and resistance to certain therapies, and scientists headed by a team at Baylor College of Medicine have now reported that MAPK4 may play an important role in triple-negative breast cancer (TNBC). Analyzing public genomic datasets, the researchers…

Researchers have identified a metabolic enzyme and pathway in triple-negative breast cancer (TNBC) patients that they hope could serve as a biomarker to select patients for targeted therapy, including one drug, CPI-613, currently in trials for other cancers. Specifically, they found that high expression of dihydrolipoamide S-succinyltransferase (DLST), a tricarboxylic…

Triple-negative breast cancer (TNBC) is notoriously difficult to treat because it lacks the receptors for estrogen, progesterone, and the growth factor HER2, all three of which can be targeted with effective cancer therapies. Standard chemotherapy regimens provide limited benefit against TNBC, and patients with metastatic disease have a poor prognosis…

Nearly 15% of all breast cancers diagnosed are tumors in the breast that do not express receptors for estrogen, progesterone, and human epidermal growth factor, dubbed triple negative breast cancer (TNBC). Among one of the hardest form of breast cancer to treat and resistant to conventional chemotherapy, TNBC is closely…

Research led by the Dana-Farber Cancer Institute and Ludwig Center at Harvard reveals a weakness of some triple negative breast cancers that could lead to better treatment for patients. They showed that inhibiting nicotinamide phosphoribosyltransferase (NAMPT), an enzyme that promotes the NAD+ salvage pathway which is often amplified in cancer,…

Therapeutics targeting RNA splicing can activate antiviral immune pathways in triple negative breast cancers (TNBC) and trigger tumor cell death, according to a study just published by researchers at Baylor College of Medicine. The study shows that endogenous mis-spliced RNA in tumor cells mimics an RNA virus, leading tumor cells…

Cambridge, U.K.-based diagnostic assay developer APIS Assay Technologies announced today a collaboration with the lab of Elsa Flores, Ph.D., and Marco Napoli, Ph.D. at Moffitt Cancer Center to assess the suitability of TROLL-2 and TROLL-3 as predictive biomarkers of cancer progression and their roll as markers of chemotherapy response. Earlier…

A discovery of four new cell types in triple negative breast cancer tumors could lead to new and more effective therapies for patients with this cancer, suggest scientists from the Garvan Institute of Medical Research in Australia. The research team used RNA sequencing to analyze gene expression in tumors taken…

A new study from New York might completely change how breast cancer is classified and treated.  Researchers have discovered, in a study of triple negative breast cancer in black women, that the molecular mechanisms involved are more closely related to non-breast cancers, and two specific gene mutations may be responsible…

Triple negative breast cancer is one of the most difficult types of breast cancer to treat, due to the mechanism being undefined. It is negative for the three most commonly mutated breast cancer markers: HER2, estrogen receptors, and progesterone receptors. It is one of the most aggressive and deadliest types…

Triple-negative breast cancers (TNBCs) are particularly aggressive, metastatic and resistant to chemotherapy treatments.  Researchers at the University of Texas MD Anderson Cancer Center have discovered that these cells alter epigenetic programing to temporarily become drug-resistant. The resistant cells switch metabolic pathways from glycolysis to mitochondrial respiration, but a new drug…

Georgia State University (GSU) researchers have just published new results showing that high levels of a certain biomarker is linked to poor prognosis in African-American patients with triple-negative breast cancer. Researchers are concerned that the dire outcome of this group could indicate that high-risk, African-American breast cancer patients are not…